4.5 Article

Rift Valley fever vaccines

Journal

VACCINE
Volume 27, Issue -, Pages D69-D72

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.07.046

Keywords

Rift Valley fever virus; MP-12; Vaccine

Funding

  1. NIAID NIH HHS [U54 AI057156, U54 AI057156-06] Funding Source: Medline

Ask authors/readers for more resources

Rift Valley fever virus (RVFV), which belongs to the genus Phlebovirus, family Bunyaviridae, is a negative-stranded RNA virus carrying a tripartite RNA genome. RVFV is transmitted by mosquitoes and causes large outbreaks among ruminants and humans in Africa and the Arabian Peninsula. Human patients develop an acute febrile illness, followed by a fatal hemorrhagic fever, encephalitis or ocular diseases, whereas ruminants experience abortions during outbreak. Effective vaccination of both humans and ruminants is the best approach to control Rift Valley fever. This article summarizes the development of inactivated RVFV vaccine, live attenuated vaccine, and other new generation vaccines. (C) 2009 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available